MAYNE PHARMA FDA Approval NDA 214154

NDA 214154

MAYNE PHARMA

FDA Drug Application

Application #214154

Documents

Label2021-04-15
Letter2021-04-16

Application Sponsors

NDA 214154MAYNE PHARMA

Marketing Status

Prescription001

Application Products

001TABLET, CHEWABLE, TABLET, CAPSULE; ORAL3MG;14.2MG0NEXTSTELLISDROSPIRENONE;ESTETROL

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2021-04-15STANDARD

Submissions Property Types

ORIG1Null40

CDER Filings

MAYNE PHARMA
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 214154
            [companyName] => MAYNE PHARMA
            [docInserts] => ["",""]
            [products] => [{"drugName":"NEXTSTELLIS","activeIngredients":"DROSPIRENONE;ESTETROL","strength":"3MG;14.2MG","dosageForm":"TABLET, CHEWABLE, TABLET, CAPSULE; ORAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
            [labels] => [{"actionDate":"04\/15\/2021","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/214154s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"04\/15\/2021","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/214154s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2021\\\/214154Orig1s000ltr.pdf\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2021-04-15
        )

)

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.